A Clinical Study of Fundus OCTA for the Identification of CMD
Recruiting now
Conditions studied: Coronary Microvascular Disease
In brief
Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.
Key facts
- Study ID
- NCT05743140
- Run by
- Peking University First Hospital
- People needed
- 400
- Starts
- 2023-03-01
- Expected to finish
- 2026-01-01
- Last updated by the study team
- 2025-08-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital;
- Complete baseline clinical information;
- Subject who have coronary angiography results, which shows coronary stenosis < 50%;
- Older than 18 years;
- Subjects who have signed informed consent.
You may not qualify if…
- Present serious fundus disease
- Severe cataract and other ophthalmic diseases, which affect imaging quality;
- Target coronary vessels provide collateral circulation for chronic complete occlusive lesions;
- The target coronary angiography agent is poorly filled, overlapped, or severely distorted, and cannot fully expose the location of the lesion;
- Coronary angiography images are of poor quality and cannot be identified;
- Active bleeding state;
- Severe renal insufficiency, contrast agent allergy, and unable to perform coronary angiography.
Where it is running
- Peking university first hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.